Flowchart of participants

Slides:

Advertisements

Similar presentations

Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center.

Advertisements

Blood pressure reduction with statins Meta-analysis of randomised controlled trials P. Strazzullo 1, S.M. Kerry 2, A. Barbato 1,2, M. Versiero 1, L. D’Elia.

TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345: Incidence of CV events in women.

Uncontrolled Hypertension, Systolic and Diastolic Blood Pressure and Development of Symptomatic Peripheral Arterial Disease in the Women’s Health Study.

TOMHS 8.3% 6.8% 18.3% 2.8% 6.6% 6.8%. Treatment of Mild Hypertension Study (TOMHS) Eligibility Visits 902 men/women Age years DBP mm Hg Free.

The TRial Of Preventing HYpertension (TROPHY) TROPHY.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:

A Global Perspective on Blood Pressure Treatment and Control in a Referred Cohort of Hypertensive Patients Bramlage P, et al. J Clin Hyper. doi: /j x.

Efficacy and Comparability of Thiazide-type Diuretics

A Controlled Trial of Renal Denervation for Resistant Hypertension

Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes Featured.

Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension Featured Article: Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra.

Chocolate Sweetens Fight Against High Blood Pressure for Some By: Karen Kaplan Los Angeles Times Presented By: Dan Pastor.

VBWG Growth in heart disease, 2000–2050 Deaths Population Foot DK et al. J Am Coll Cardiol. 2000;35:

Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of a Fixed-Dose Combination Strategy on Adherence.

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Renal Denervation in Moderate Treatment-Resistant.

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effectiveness of Foot Orthoses to Treat Plantar Fasciitis:

Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Exercise and Weight Loss Reduce Blood Pressure in.

Study design: a randomized placebo- controlled crossover trial of 2 periods of 4 weeks Nicole A.J. van der Linde, et al. Hypertension 2006;47;

Date of download: 6/27/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Reference Values for Self-recorded Blood Pressure:

Baseline characteristics of HPS participants by prior cerebrovascular disease.

Search strategy and results Amir Kashani, et al. Circulation. 2006;114:

Volume 54, Pages S135-S139 (December 1998)

ACCORD Design and Baseline Characteristics

Copyright © 2010 American Medical Association. All rights reserved.

From ESH 2016 | POS 7D: Jan Rosa, MD

Copyright © 2011 American Medical Association. All rights reserved.

CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.

Baseline Characteristics of 167 Patients Randomly Assigned to Either Placebo or Extended-Release Niacin Allen J. Taylor et al. Circulation 2004; 110:

Neal B, et al. Diabetes Care 2015;38:403–411

Copyright © 2008 American Medical Association. All rights reserved.

Characteristics of the Folic Acid and Placebo Groups at the Start of the Study J. Durga et al. Arch Intern Med. 2005;165:

Mean 24-Hour, Daytime, and Night Ambulatory Systolic BP, Diastolic BP, and PP Before (Week 0) and After (Week 12) NAG and Placebo Intake in 37 Hypertensive.

Copyright © 2007 American Medical Association. All rights reserved.

Attenuation of the “White-Coat Effect” by Antihypertensive Treatment and Regression of Target Organ Damage by Gianfranco Parati, Luisa Ulian, Lorena Sampieri,

by Katie Ayers, Loretta M. Byrne, Anthony DeMatteo, and Nancy J. Brown

Cholesterol and blood pressure values at baseline and after 15 days of dark-chocolate and white-chocolate consumption Characteristic Dark chocolate before.

AARDVARK Trial design: Patients with small abdominal aortic aneuryms (AAAs) were randomized in a 1:1:1 fashion to either perindopril 10 mg once daily,

Bakris GL, Burkhart JM, Weinhandl ED, McCullough PA, Kraus MA

Bakris GL, Burkhart JM, Weinhandl ED, McCullough PA, Kraus MA

PREMIER: Rate of hypertension at 18 months

Section 7: Aggressive vs moderate approach to lipid lowering

Why double blind, controlled randomized trials?

Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

Time point Difference in systolic BP (mm Hg) p

End point Net change with soy supplements vs control (95% CI) p

© The Author(s) Published by Science and Education Publishing.

Chapter 28 Nutrition, Lifestyle, and Hypertension

Life expectancy and baseline BP: Male participants

Adjusted relative risk for developing end-stage renal disease (ESRD) associated with blood-pressure level BP level (mm Hg) Adjusted relative risk 95%

Volume 91, Issue 5, Pages (May 2017)

William T. Abraham et al. JCHF 2015;3:

Total number of screenings in 2016

DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.

Baseline Lipid Parameters and Characteristics Among 3110 Men According to Quintiles of Total Cholesterol Ruben O. Halperin et al, Hypertension 2006;47;45-50.

Flow chart of the 1683 study members at age 60–64 years by hypertension (HT) status. Flow chart of the 1683 study members at age 60–64 years by hypertension.

Demographic and Clinical Characteristics (means ± SD or %) of Subjects in Different Office SBP and DBP Categories Mancia G et al Hypertension. 2005;45:1072.

Volume 81, Issue 4, Pages (February 2012)

Volume 54, Pages S135-S139 (December 1998)

Kaplan-Meier Curves for the Percentages of Subjects with Microalbuminuria during Treatment with Trandolapril plus Verapamil or Placebo Piero Ruggenenti.

Volume 71, Issue 9, Pages (May 2007)

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

End point Valsartan Valsartan+HCTZ p

(D) Systolic blood pressure (BP) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. . (D) Systolic blood pressure.

Effects of placebo or carvedilol CR on 24-hour mean systolic blood pressure and diastolic blood pressure obtained by ambulatory monitoring in hypertensive.

Role of - Azilsartan - Azilsartan/chlorthalidone

The combined effects of low sodium and the DASH diet according to baseline blood pressure. The combined effects of low sodium and the DASH diet according.

The distribution of systolic blood pressure (SBP) in male (blue) and female (red) athletes with mean values (SD) presented for each sex (panel A). The.

Average change in blood pressure (BP) from recruitment to 6-month postrecruitment in intervention and control patients >50 years included due to having.

Presentation transcript:

Flowchart of participants Beatrice A. Golomb, et al. Arch Intern Med. 2008;168:721-727

Randomized Substudy Groups Compared at Baseline Beatrice A. Golomb, et al. Arch Intern Med. 2008;168:721-727

BP Difference, Statin Groups vs Placebo Beatrice A. Golomb, et al. Arch Intern Med. 2008;168:721-727

Difference between the statin and placebo groups A, Systolic blood pressure (SBP), change from baseline. This figure shows values for subjects who were not hypertensive at baseline, were never prescribed BP medications, and had BP measured through the 8-month visit. This mitigates the influence of changes distinct from treatment assignment across time. The change values differed significantly from placebo (P<.05) at month 6 (only) for both pravastatin sodium and simvastatin. Standard errors for pravastatin: month 1, 1.3; month 6, 1.2; month 8, 1.2. Standard errors for simvastatin: month 1, 1.2; month 6, 1.2; month 8, 1.2. P values for pravastatin: month 1, P =.18; month 6, P =.04; month 8, P =.69. P values for simvastatin: month 1, P =.30; month 6, P =.02; month 8, P =.18. B, DBP, change from baseline. This figure shows values for subjects who were not hypertensive at baseline, were never prescribed BP medications, and had BP measured through the 8-month visit. This mitigates the influence of changes distinct from treatment assignment across time. The change values differed significantly from placebo (P<.01) at month 6 (only) for both pravastatin and simvastatin. Standard errors for pravastatin: month 1, 0.98; month 6, 0.96; month 8, 1.0. Standard errors for simvastatin: month 1, 0.97; month 6, 0.98; month 8, 1.0. P values for pravastatin: month 1, P =.06; month 6, P =.004; month 8, P =.06. P values for simvastatin: month 1, P =.46; month 6, P =.01; month 8, P =.66. B.A. Golomb, et al. Arch Intern Med 2008;168:721-727